Song et al., 2012 - Google Patents
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivoSong et al., 2012
View HTML- Document ID
- 11542050122345883881
- Author
- Song D
- Ye Q
- Poussin M
- Harms G
- Figini M
- Powell Jr D
- Publication year
- Publication venue
- Blood, The Journal of the American Society of Hematology
External Links
Snippet
The costimulatory effects of CD27 on T lymphocyte effector function and memory formation has been confined to evaluations in mouse models, in vitro human cell culture systems, and clinical observations. Here, we tested whether CD27 costimulation actively enhances …
- 210000001744 T-Lymphocytes 0 title abstract description 201
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Song et al. | CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo | |
Wing et al. | Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager | |
Sakemura et al. | A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration | |
US20240141041A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF | |
Guedan et al. | Engineering and design of chimeric antigen receptors | |
US10869889B2 (en) | Method and compositions for cellular immunotherapy | |
Yamamoto et al. | T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy | |
Ahmed et al. | Regression of experimental medulloblastoma following transfer of HER2-specific T cells | |
US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
Qin et al. | Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein | |
CN111247242B (en) | Chimeric Antigen Receptors (CARs), compositions, and methods of use thereof | |
Song et al. | In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | |
CN107849112B (en) | Chimeric Antigen Receptors (CAR), compositions and methods of use thereof | |
Urbanska et al. | A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor | |
KR102483822B1 (en) | Tagged chimeric effector molecules and receptors thereof | |
US20190175651A1 (en) | Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression | |
Thomas et al. | An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers | |
US11667693B2 (en) | Synthetic biology-based ADCC technology | |
US20210214415A1 (en) | Immunoresponsive cells expressing dominant negative fas and uses thereof | |
JP2023521037A (en) | Enhanced adoptive cell transfer | |
Nasiri et al. | T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts | |
JP7296133B2 (en) | GENETICALLY MODIFIED CELL AND METHOD FOR PRODUCING THE SAME | |
US20210401890A1 (en) | Chimeric antigen receptor t lymphocyte for treating tumors, preparation method therefor, and use thereof | |
Albert et al. | Tonic signaling and its effects on lymphopoiesis of CAR-armed hematopoietic stem and progenitor cells | |
US20240173409A1 (en) | Enhancing t cell function through the use of proximal signaling molecules |